Edwards Lifesciences Corporation Overview
Pro stress-test →Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. The company specializes in transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical heart valves. For 2025, the company delivered full-year sales growth of 11.5% and projects 2026 constant-currency sales growth of 8% to 10% with adjusted EPS of $2.90 to $3.05.
Strategic Profile
Pro stress-test →Edwards' strategy focuses on three key elements: focusing solely on structural heart, solving large, urgent and very complex patient needs, and pursuing unique opportunities to innovate and lead. Strong demand for transcatheter valve therapies and expanding mitral and tricuspid portfolio drive double-digit quarterly growth. The company benefits from 70 years of valve innovation expertise and world-class clinical evidence supporting long-term product durability.
Competitive Landscape
Pro stress-test →Edwards Lifesciences dominates the structural heart market with leading positions in TAVR and mitral/tricuspid therapies. Primary competitors include Boston Scientific (Watchman, Acurate neo2), Abbott Laboratories (MitraClip, Sapien competitors), and Medtronic (CoreValve). Edwards maintains competitive advantages through its SAPIEN franchise, TMTT portfolio depth, and extensive clinical evidence from the PARTNER trial program. The market is characterized by high barriers to entry due to regulatory complexity and clinical data requirements.
Industry Context
Edwards Lifesciences Corporation operates in Medical Devices - Cardiovascular.
Key facts
Founded: 1958 · Headquarters: Irvine, US · Revenue: $6.4B